To determine whether GIP is important after RYGB, patients without diabetes who underwent RYGB were given the DPP-4 inhibitor sitagliptin to increase the bioavailability of both GLP-1 and GIP [146,156]. The gene discussed is GCG; the disease is diabetes mellitus.